Premium
Imatinib mesylate effectively combines with chaperone‐rich cell lysate‐loaded dendritic cells to treat bcr‐abl + murine leukemia
Author(s) -
Zeng Yi,
Graner Michael W.,
Feng Hanping,
Li Gang,
Katsanis Emmanuel
Publication year - 2004
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.20115
Subject(s) - imatinib mesylate , imatinib , cancer research , myeloid leukemia , immunotherapy , leukemia , abl , breakpoint cluster region , medicine , immunology , tyrosine kinase , receptor , immune system
Imatinib mesylate has become an effective agent for the treatment of chronic myeloid leukemia (CML). However, the development of drug resistance has led to examination of combination therapies. In this study, we investigated the effects of combining imatinib with immunotherapy against a murine bcr‐abl + leukemia, 12B1. We have previously shown that multiple chaperone proteins may be enriched into a vaccine form from tumor cell lysates by a free‐solution isoelectric focusing method. We refer to these vaccines as chaperone‐rich cell lysates (CRCLs) and have found that they are potent immunologic agents against a variety of murine tumors, including 12B1. We now demonstrate that the combination of imatinib with dendritic cells loaded with 12B1‐derived CRCL yields high activation of anti‐12B1‐specific T cells and potent antitumor activity, resulting in tumor‐free survival in up to 63% of mice with bcr‐abl + 12B1 tumors. Our data suggest that immunotherapy can be effectively combined with imatinib for the treatment of CML. © 2004 Wiley‐Liss, Inc.